Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 14/20 | 0.45 |
| ▸ | HTR2A | P28223 | 12/20 | 0.45 |
| ▸ | HTR2B | P41595 | 11/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972303 | 0.88 | KDR (0.61) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972419 | 0.86 | KDR (0.67) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972320 | 0.83 | KDR (0.49) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972314 | 0.83 | KDR (0.59) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972322 | 0.82 | KDR (0.58) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972255 | 0.82 | KDR (0.58) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972321 | 0.82 | KDR (0.65) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL2781030 | 0.80 | NOTUM (0.43) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972326 | 0.77 | CDK8 (0.74) | KDRCDK1CDK2CDK8FLT1 | |
| SCHEMBL12972266 | 0.77 | CDK8 (0.73) | KDRCDK1CDK2CDK8FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885CDK1 26/4885CDK2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.